Surviving a Bear Market

After the longest bull run in biotech history, the sector is working its way through a prolonged downturn.

While there have been signs of a thaw as positive catalysts buoy investor sentiment, a recovery now appears to be on hold as inflation and rising interest rates foster a risk-off environment. That means public and private companies in need of capital will likely still need to accept a reset valuation or pursue higher-risk alternatives.

Many biopharma executives and investors haven’t lived through a bear market like this. That’s why it’s time to rely on BioCentury's strategic intelligence to inform your decisions as you navigate your company through turbulent times.

Sign up now (free) to take advantage of this special access, and put BioCentury to work for you.